Dr. Reddy’s一季度利润同比降69%，受₹240 crore司美格鲁肽API拨备拖累

Wall Street mixed as investors eye tech earnings for AI cues, led by Alphabet
Introduction & Market Context
Dr. Reddy’s Laboratories (NYSE:RDY) presented its first quarter fiscal 2027 results on July 22, 2026, revealing a complex picture of underlying business strength overshadowed by a significant semaglutide API setback. While the company emphasized "healthy double-digit base business growth" across geographies, reported profitability metrics fell sharply due to a ₹240 crore ($25 million) provision related to semaglutide quality issues. The stock declined 7.44% to $11.63, trading near its 52-week low of $11.54, as investors focused on the earnings miss and margin pressure despite management’s optimistic outlook.
The Indian pharmaceutical company reported consolidated revenues of ₹8,071 crores ($853 million), representing 6% year-over-year growth and 7% sequential growth. However, EBITDA margin compressed to 12.5% from 26.7% a year earlier, and profit after tax attributable to equity shareholders fell 69% year-over-year to ₹443 crores.
Financial Performance Highlights
The presentation revealed that excluding the semaglutide API impact, Dr. Reddy’s underlying financial performance remained robust. As detailed in the company’s financial analysis, EBITDA margin would have been 15.4% rather than the reported 12.5%, and profit before tax margin would have reached 9.8% versus the reported 6.8%.
The semaglutide-related provision of ₹240 crores included inventory write-downs and other associated costs after certain batches were found to be out of specification due to an API issue. Management indicated that commercial supply is expected to resume in November 2026 following completion of testing and remediation work.
Beyond the semaglutide impact, the company noted that EBITDA margins were further pressured by higher solvent and freight costs arising from Middle East geopolitical conflicts. Despite these headwinds, Dr. Reddy’s maintained a net cash surplus of ₹3,058 crores and reported return on capital employed of 5.3% (8% excluding semaglutide impact).
The company’s quarterly trend analysis shows the dramatic impact of the semaglutide issue on recent performance compared to the previous three quarters.
Geographic Performance Analysis
Dr. Reddy’s diversified geographic footprint demonstrated resilience during the quarter, with the company noting double-digit base business growth across all major markets when excluding lenalidomide sales declines.
North America delivered mixed results, with reported revenues of ₹2,205 crores showing 35% year-over-year growth but declining when adjusted for lower lenalidomide sales and prior quarter shelf stock adjustments. The company launched six new products during the quarter, including a first-to-market launch of anti-cancer drug bosutinib 400mg with 180-day exclusivity. Dr. Reddy’s also became the first company to launch generic semaglutide injection for Type 2 Diabetes in Canada.
India emerged as a strong performer with revenues of ₹1,718 crores, up 17% year-over-year and 10% sequentially. The domestic business maintained its #9 rank in the Indian pharmaceutical market and achieved #1 position in stomatologicals and #2 in vaccines. The company launched generic semaglutide tablets in India and introduced Celevida GLP+ nutrition offerings through a collaboration with Nestlé. Notably, toripalimab, a novel in-licensed oncology drug, entered the ₹100 crore club in less than two years since launch.
Emerging Markets posted the strongest year-over-year growth at 31%, reaching ₹1,718 crores, driven by new product launches and favorable foreign exchange movements. The region now accounts for 23% of total revenues, with Russia contributing 49% of the segment at ₹903 crores.
Europe generated ₹1,444 crores with 13% year-over-year growth, though sequential growth was flat at 0.6%. The company noted that nicotine replacement therapy (NRT) revenues declined due to an operating model change post-integration with Haleon, where rebates and discounts shifted to distributors. Management characterized this change as profit-neutral.
Strategic Initiatives and Product Pipeline
The presentation highlighted several strategic achievements beyond the headline financial results. Dr. Reddy’s celebrated 25 years of NYSE listing, remaining the first and only Indian pharmaceutical company on the exchange. The company was placed in the top 1% globally by FTSE Russell and ranked 165th globally among TIME-Statista World’s Most Sustainable Companies.
On the product development front, Dr. Reddy’s filed five ANDAs and one NDA in the US market during the quarter, with 76 ANDAs and 3 NDAs pending approval, including 46 Para IV filings and 24 first-to-file opportunities. The company also received Fast Track Designation from the FDA for partnered product COYA 302 for ALS treatment and filed a Marketing Authorization Application for abatacept IV presentation with the European Medicines Agency.
The company partnered with Innoviva Specialty Therapeutics to develop and commercialize XACDURO, a critical-care antibiotic, across select emerging markets including South and Central America, the Caribbean, Russia and CIS countries.
Challenges and Regulatory Updates
The presentation acknowledged operational challenges beyond the semaglutide issue. Dr. Reddy’s received a Form 483 with seven observations following a pre-license inspection at its biologics facility in Bachupally in June 2026. The company responded within the required timeline, though this adds a potential risk factor to the anticipated December 2026 approval of its abatacept biosimilar.
The PSAI (Pharmaceutical Services and Active Ingredients) segment, which accounts for 11% of revenues, saw gross margins compress to 4.5% from 13.2% a year earlier, primarily due to the semaglutide API impact. Excluding this effect, PSAI gross margins would have been 12.9%, closer to historical levels.
Forward-Looking Outlook
Management maintained its long-term margin target of approximately 20% EBITDA margin, expressing confidence in reaching this level in the coming quarters. The company expects to achieve this target even without semaglutide contribution initially, with potential to exceed it once semaglutide supplies resume.
Dr. Reddy’s outlined six strategic pillars going forward: strengthening core businesses while building future growth drivers in peptides, biosimilars, consumer health and innovative assets; advancing key products including semaglutide and abatacept; driving operational efficiencies; augmenting organic growth with M&A and in-licensing; enhancing capabilities in people, digital and processes; and maintaining focus on quality, compliance and sustainability.
The company expects to launch 27 products in the US market during fiscal 2027, with at least one material launch anticipated in the next quarter with tens of millions of dollars in revenue potential. Capital expenditure guidance was reduced to approximately ₹1,800 crores for the full year from the previous ₹2,500-2,700 crore range, while R&D spending is expected to remain at 7-8% of revenues.
For semaglutide specifically, management indicated API testing should complete by the third week of September 2026, with commercial supply resumption targeted for November. The company aims to supply 6-7 million pens between November and March across Canada, India and partner markets, though executives noted an 80-90% success probability rather than certainty.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.